NASDAQ: UPBUpstream Bio Inc Stock
$6.10-0.28 (-4.39%)
Updated Jun 12, 2026
UPB Price
$6.10
Fair Value Price
-$1.40
Market Cap
$331.96M
52 Week Low
$5.85
52 Week High
$33.68
P/E
-2.1x
P/B
1.09x
P/S
147.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.32M
Earnings
-$156.76M
Gross Margin
100%
Operating Margin
-4,718.96%
Profit Margin
-4,719%
Debt to Equity
0.05
Operating Cash Flow
-$140M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UPB Overview
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UPB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
UPB
Ranked#402 of 463
Ranked#402 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important UPB news, forecast changes, insider trades & much more!
UPB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UPB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPB ($6.10) is overvalued by 536.4% relative to our estimate of its Fair Value price of -$1.40 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UPB ($6.10) is not significantly undervalued (536.4%) relative to our estimate of its Fair Value price of -$1.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UPB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UPB due diligence checks available for Premium users.
Valuation
UPB fair value
Fair Value of UPB stock based on Discounted Cash Flow (DCF)
Price
$6.10
Fair Value
-$1.40
Undervalued by
536.40%
UPB ($6.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UPB ($6.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UPB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UPB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.1x
Industry
16.53x
Market
14.15x
UPB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
4.85x
UPB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UPB's financial health
Profit margin
Revenue
$1.0M
Net Income
-$40.6M
Profit Margin
-3,925.6%
UPB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
UPB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$318.1M
Liabilities
$14.1M
Debt to equity
0.05
UPB's short-term assets ($316.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPB's short-term assets ($316.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$47.9M
Investing
$42.4M
Financing
$598.0k
UPB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UPB vs Biotech Stocks
Upstream Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.